• Sihan Peng, Ziyan Xie, Xiyu Zhang, Ya Liu, Xiangeng Zhang, Xiaoli Liang, Hongyan Wang, and Chunguang Xie.
• Hospital of Chengdu University of Traditional Chinese Medicine.
• Medicine (Baltimore). 2021 Jan 22; 100 (3): e23918e23918.

BackgroundObesity is an independent risk factor for the occurrence and development of diabetes. Patients with diabetes combined with obesity will face serious burdens such as increase in insulin resistance and difficulty in blood glucose control. As a safe, effective, economical, and simple intervention, Tuina is more acceptable to the public than drugs. The objective of this systematic evaluation and meta-analysis is to evaluate the efficacy and safety of Tuina for diabetes with obesity.MethodsWe will search the following electronic databases: PubMed, Embase, Cochrane Library, Web of science, Chinese National Knowledge Infrastructure (CNKI), Sino Med, Wanfang, Chinese Clinical Trial Registry System, China Biomedical Literature Database (CBM). The time limit for retrieving studies is from establishment to November 2020 for each database. Randomized controlled clinical trials related to Tuina intervention on diabetes with obesity will be included. Data synthesis, sensitivity analysis, subgroup analysis as well as the assessment of bias risk will be conducted by using Stata V.13.0 and Review manager 5.3 software.ResultsThis study will provide a quantitative and standardized evaluation for the efficacy of Tuina therapy on diabetes with obesity.ConclusionThis systematic review and meta-analysis will provide the high-quality evidence of whether Tuina is an effective intervention for diabetes with obesity.Registration NumberINPLASY2020110106.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

28 keywords...

hide…